Radiation‐induced xerostomia in patients with head and neck cancer
Top Cited Papers
- 31 October 2006
- Vol. 107 (11) , 2525-2534
- https://doi.org/10.1002/cncr.22302
Abstract
A dry mouth or xerostomia is one of the most common complications during and after radiotherapy for head and neck cancer, because irreparable damage is caused to the salivary glands, which are included in the radiation fields. Xerostomia not only significantly impairs the quality of life of potentially cured cancer patients, it may also lead to severe and long‐term oral disorders. Because management of xerostomia is rarely effective, prevention is paramount. Several strategies have been developed to avoid radiation‐induced salivary dysfunction without compromising definitive oncologic treatment. These include salivary gland‐sparing radiation techniques, such as 3‐dimensional conformal or intensity‐modulated radiotherapy, concomitant cytoprotectants, and surgical salivary gland transfer. However, these preventive approaches are not applicable to all patients, and comprehensive scientific research that incorporates new biological insights is warranted to optimize the therapeutic index of radiotherapy for head and neck cancer. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 102 references indexed in Scilit:
- 3D MR sialography protocol for postradiotherapy follow-up of the salivary duct systemJournal of Magnetic Resonance Imaging, 2006
- Mobilization of Bone Marrow Stem Cells by Granulocyte Colony-Stimulating Factor Ameliorates Radiation-Induced Damage to Salivary GlandsClinical Cancer Research, 2006
- Dose–response relationships within the parotid gland after radiotherapy for head and neck cancerRadiotherapy and Oncology, 2004
- Speech Intelligibility and Quality of Life in Head and Neck Cancer SurvivorsThe Laryngoscope, 2004
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivitySeminars in Oncology, 2002
- Oral complications in the head and neck radiation patientSupportive Care in Cancer, 2002
- The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effectsRadiotherapy and Oncology, 1995
- LENT SOMA tables table of contentsRadiotherapy and Oncology, 1995
- Parotid gland function during and following radiotherapy of malignancies in the head and neckEuropean Journal Of Cancer, 1992